GROSSI, FRANCESCO
 Distribuzione geografica
Continente #
EU - Europa 692
Totale 692
Nazione #
IT - Italia 692
Totale 692
Città #
Genova 428
Rapallo 156
Genoa 100
Bordighera 8
Totale 692
Nome #
Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely, file e268c4ca-e8e9-a6b7-e053-3a05fe0adea1 251
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab, file e268c4ca-5ff0-a6b7-e053-3a05fe0adea1 78
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study, file e268c4c8-c8c7-a6b7-e053-3a05fe0adea1 67
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy, file e268c4cc-cf27-a6b7-e053-3a05fe0adea1 58
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy, file e268c4cc-f3f7-a6b7-e053-3a05fe0adea1 56
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients, file e268c4cc-e1c1-a6b7-e053-3a05fe0adea1 55
Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy”, file e268c4cd-5a19-a6b7-e053-3a05fe0adea1 47
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy, file e268c4cc-e011-a6b7-e053-3a05fe0adea1 43
Gefitinib treatment outcome after progression on erlotinib in patients with advanced non-small-cell lung cancer (NSCLC), file e268c4c7-66bd-a6b7-e053-3a05fe0adea1 3
Disease stabilization as a surrogate end point in advanced non small cell lung cancer patients treated with erlotinib or gefitinib, file e268c4c7-66bf-a6b7-e053-3a05fe0adea1 3
Skin toxicities difference between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC), file e268c4c7-6def-a6b7-e053-3a05fe0adea1 3
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: Can we use enemy territory at our advantage?, file e268c4cc-d50a-a6b7-e053-3a05fe0adea1 3
Afatinib for the treatment of non-small cell lung cancer, file e268c4cc-dd48-a6b7-e053-3a05fe0adea1 3
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer, file e268c4cc-e924-a6b7-e053-3a05fe0adea1 3
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy, file e268c4ca-7907-a6b7-e053-3a05fe0adea1 2
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis, file e268c4cc-e928-a6b7-e053-3a05fe0adea1 2
Difference in skin toxicity incidence between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC), file e268c4c7-7396-a6b7-e053-3a05fe0adea1 1
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus., file e268c4ca-464d-a6b7-e053-3a05fe0adea1 1
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers, file e268c4cc-cd58-a6b7-e053-3a05fe0adea1 1
Vinflunine for the treatment of non-small cell lung cancer, file e268c4cc-cd62-a6b7-e053-3a05fe0adea1 1
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine, file e268c4cc-d50e-a6b7-e053-3a05fe0adea1 1
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds, file e268c4cc-d51b-a6b7-e053-3a05fe0adea1 1
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer, file e268c4cc-e01e-a6b7-e053-3a05fe0adea1 1
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression, file e268c4cc-e1c3-a6b7-e053-3a05fe0adea1 1
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer, file e268c4cc-e1d0-a6b7-e053-3a05fe0adea1 1
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial, file e268c4cc-eada-a6b7-e053-3a05fe0adea1 1
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer, file e268c4cc-f3f5-a6b7-e053-3a05fe0adea1 1
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer, file e268c4cc-f3f9-a6b7-e053-3a05fe0adea1 1
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer, file e268c4cc-f3fb-a6b7-e053-3a05fe0adea1 1
Understanding the checkpoint blockade in lung cancer immunotherapy, file e268c4cd-3e0d-a6b7-e053-3a05fe0adea1 1
Exosomes: a new horizon in lung cancer, file e268c4cd-5f48-a6b7-e053-3a05fe0adea1 1
Totale 692
Categoria #
all - tutte 1.832
article - articoli 1.822
book - libri 0
conference - conferenze 10
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.664


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202058 0 0 0 0 0 7 6 6 12 7 15 5
2020/2021155 4 11 16 9 10 11 4 8 36 22 9 15
2021/2022215 29 7 12 27 19 9 10 8 5 12 60 17
2022/2023174 4 8 48 27 7 44 6 12 4 2 12 0
2023/202480 0 3 8 4 9 4 34 9 4 2 3 0
Totale 692